|
I agree that a lot of the research is done in universities, but it's still funded by companies like AstroZeneca and GlaxoSmithKline. My basic argument does, I believe, still hold. No profit from sales of the rare successful drug inevitably leads to fewer (or, if we take it to its logical conclusion, no) new drugs. The companies need to make billions from the drugs which do work to pay for all the ones which don't.
|